Novel approach may prevent antibodies from triggering immune rejection of transplant cells
Until recently, most CAR-T therapies were made from the patient’s own cells, but the long-term commercial viability of cell therapies of all types will rely on “allogeneic” cells, therapeutic cells mass-produced and grown from a source outside the patient. However, the recipient’s immune system is likely to treat all outside cells as foreign and reject […]